Search

Your search keyword '"Barbara H. Garmy-Susini"' showing total 17 results
Start Over Author "Barbara H. Garmy-Susini"
17 results on '"Barbara H. Garmy-Susini"'

1. Supplementary Table S6 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

HIGH CD36 gene signature generated from upregulated genes in AML patients that express the most CD36 mRNA compared to that of the lowest expression of CD36 in TCGA cohort.

Published
2023

2. Supplementary Table S7 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Summary of all GSEA data identified in AraC- versus PBS-treated AML cells in PDX and LOW versus HIGH Responder to AraC in PDX.

Published
2023

3. Supplementary Table S1 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

(1) Clinical characteristics of 27 AML patients used in this study for engraftment in NSG mice, including the 25 ones treated in vivo with 60 mg/kg/d cytarabine (AraC) for 5 days. (2) Clinical and mutational characteristics of AML cell lines used in this study.

Published
2023

4. Supplementary Table S5 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Up- and down-regulated genes in AML patients that have the lower response (LowR) to AraC in vivo in NSG mice compared to high responder (HighR) to AraC in vivo using PDX assay.

Published
2023

5. Supplementary Table S2 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Determination of LICs frequency in bone marrow and spleen from AraC- or PBS-treated AML-xenografted NSG mice using in vivo limiting dilution assay.

Published
2023

6. Supplementary Table S3 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

(1) Gene signatures of AraC residual AML blasts in vivo from three AML patients xenografted and treated with AraC. (2) Functional analyses of up-regulated genes of AraC residual AML blasts in vivo. (3) Functional analyses of down-regulated genes of AraC residual AML blasts in vivo. (4) Prognostic analysis of the up- and down- regulated gene signatures of AraC-residual AML blasts in vivo in three independently published cohorts of AML patients.

Published
2023

7. Supplementary Methods and Supplementary Figures 1 through 18 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

Supplementary Methods. Supplementary Figure S1. Clinical distributions of AML patients from TUH and 3 independent patient cohorts. Supplementary Figure S2. In vivo treatment with 60 mg/kg/d of cytarabine (AraC) given daily for 5 days induces a significant reduction of the total cell tumor burden in AML-engrafted mice. Supplementary Figure S3. In vivo cytarabine (AraC) treatment induces significant but heterogeneous response in bone marrow and spleen of AML-xenografted NSG mice. Supplementary Figure S4. Comparative analysis of the in vivo response to cytarabine (AraC) with clinicobiological data of AML patients. Supplementary Figure S5. In vivo cytarabine (AraC) treatment induces changes in CD34+/-CD38+/- phenotypes in AML-engrafted mice. Supplementary Figure S6. In vivo cytarabine (AraC) chemotherapy treatment leads to reduction of the absolute number of human CD34+CD38+/- populations in AML. Supplementary figure S7. No enrichment in G0 quiescent cells was observed in mice treated with sublethal dose of cytarabine (AraC) for 5 days in vivo. Supplementary figure S8. Mitochondrial and energetic features of LOW (KG1, KG1a, U937) and HIGH (MOLM14, MV4-11, HL60) OXPHOS AML cell lines. Supplementary figure S9. Functional analysis of the transcriptomes of LOW (KG1a, U937) versus HIGH (MOLM14, HL60) OXPHOS AML cell lines untreated or treated with metformin. Supplementary figure S10. AML cells surviving after cytarabine (AraC) treatment are resistant to chemotherapies and are pre-existing CD36+CD44+ phenotype with an increased oxidative metabolism. Supplementary figure S11. Culture in galactose induces energetic shift of LOW OXPHOS AML U937 cells toward HIGH OXPHOS state, leading to cytarabine (AraC) resistance in AML. Supplementary figure S12. Energetic shift of mtDNA-depleted Rho0 MOLM14 cells toward LOW OXPHOS state induces AraC sensitivity. Supplementary figure S13. Electron Transfer Chain Complex I inhibition by Phenformin (Phenf) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S14. Electron Transfer Chain Complex I inhibition by Metformin (Met) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S15. Electron Transfer Chain Complex I inhibition by Rotenone (Rot) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S16. Electron Transfer Chain Complex III inhibition by Antimycin A (AntiA) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S17. Electron Transfer Chain Complex III inhibition by Atovaquone (ATQ) induces energetic shift toward LOW OXPHOS state and increases cytarabine (AraC) sensitivity in MOLM14 cells. Supplementary figure S18. Working model of the resistance to AraC in vivo.

Published
2023

8. Supplementary Table S4 from Chemotherapy-Resistant Human Acute Myeloid Leukemia Cells Are Not Enriched for Leukemic Stem Cells but Require Oxidative Metabolism

Author

Jean-Emmanuel Sarry, Christian Récher, Martin Carroll, Gwenn Danet-Desnoyers, Mary Selak, François Vergez, Jean-Charles Portais, Barbara H. Garmy-Susini, François Delhommeau, Lara Gales, Tony Palama, Pierre Hirsch, Yara Barreira, Olivier Duchamp, Yves Collette, Emmanuel Griessinger, Rémy Castellano, Camille Montersino, Laetitia K. Linares, Jason Iacovoni, Laurent Vallar, Tony Kaoma, Suzanne Tavitian, Audrey Sarry, Nizar Serhan, Marion David, Nicolas Broin, Stéphanie Cassant-Sourdy, Marie-Laure Nicolau-Travers, Virginie Féliu, Héléna Boutzen, Clément Larrue, Sarah Scotland, Marine Fraisse, Lucille Stuani, Mayumi Sugita, Claudie Bosc, Robin Perry, Mohsen Hosseini, Nesrine Aroua, Fabienne de Toni, Estelle Saland, and Thomas Farge

Abstract

(1) HIGH OXPHOS gene signature generated from HIGH versus LOW OXPHOS AML cell lines untreated or treated with metformin. (2) Functional analysis of upregulated genes encoding for mitochondrial proteins in untreated HIGH versus LOW OXPHOS AML cell lines.

Published
2023

9. Supplemental Figure 2 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S2. Expression of endogenous VEGF-D in mice tissues

Published
2023

10. Supplemental Figure 5 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S5. VEGF-D 5'UTR mRNA exhibits two structural forms that allow the binding of different proteins

Published
2023

11. Supplemental Figure 7 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S7. Tumor growth after NSAID treatment

Published
2023

12. Data from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

The vascular endothelial growth factor VEGF-D promotes metastasis by inducing lymphangiogenesis and dilatation of the lymphatic vasculature, facilitating tumor cell extravasion. Here we report a novel level of control for VEGF-D expression at the level of protein translation. In human tumor cells, VEGF-D colocalized with eIF4GI and 4E-BP1, which can program increased initiation at IRES motifs on mRNA by the translational initiation complex. In murine tumors, the steady-state level of VEGF-D protein was increased despite the overexpression and dephosphorylation of 4E-BP1, which downregulates protein synthesis, suggesting the presence of an internal ribosome entry site (IRES) in the 5′ UTR of VEGF-D mRNA. We found that nucleolin, a nucleolar protein involved in ribosomal maturation, bound directly to the 5′UTR of VEGF-D mRNA, thereby improving its translation following heat shock stress via IRES activation. Nucleolin blockade by RNAi-mediated silencing or pharmacologic inhibition reduced VEGF-D translation along with a subsequent constriction of lymphatic vessels in tumors. Our results identify nucleolin as a key regulator of VEGF-D expression, deepening understanding of lymphangiogenesis control during tumor formation. Cancer Res; 76(15); 4394–405. ©2016 AACR.

Published
2023

13. Supplemental Figure 8 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S8. Schematic representation of VEGF-D synthesis in tumor cells

Published
2023

14. Supplementary Figure Legend from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Supplementary figure legend

Published
2023

15. Supplemental Figure 6 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S6. Polysome profiling of 4T1 cells

Published
2023

16. Supplemental Figure 4 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S4. Lymphangiogenesis and tumor gowth are not affected by 4T1 or 67NR lentiviral transduction

Published
2023

17. Supplemental Figure 3 from Nucleolin Promotes Heat Shock–Associated Translation of VEGF-D to Promote Tumor Lymphangiogenesis

Author

Barbara H. Garmy-Susini, Anne-Catherine Prats, Robert J. Schneider, Stefano Marzi, Julie Guillermet-Guibert, Jose Courty, Stephane Pyronnet, Frederic Lopez, Laetitia Ligat, Anne Gomez-Brouchet, Françoise Pujol, Stephanie Cassant-Sourdy, Anne-Catherine Helfer, Aurelien Adoue, Fransky Hantelys, Florence Tatin, and Florent Morfoisse

Abstract

Figure S3. Podoplanin staining of lymphatic vessels

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results